BTK and B-cell chronic lymphocytic leukemia: The first‐in‐class BTK inhibitor (BTKi) ibrutinib first received US Food and Drug Administration (FDA) approval in 2014 for the treatment of patients with CLL who had received at least one previous therapy, including those with 17p deletion (del(17p)) [1–5].